down arrow

PMV Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Miscellaneous
  • ISIN: US69353Y1038
USD
1.28
0.05 (4.07%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.261.30

52 Week

0.811.84
Valuation
Technical
Day's Volume

CASH

209.44 k

Shareholding (Mar 2025)

FII

15.46%

Held by 50 FIIs

DII

47.97%

Held by 30 DIIs

Promoter

13.35%

How big is PMV Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, PMV Pharmaceuticals, Inc. has a market capitalization of 56.63 million, with net sales of 0.00 million and a net profit of -60.88 million over the latest four quarters. The company reported shareholder's funds of 176.08 million and total assets of 191.29 million as of Dec 24.

Market Cap: As of Jun 18, PMV Pharmaceuticals, Inc. has a market capitalization of 56.63 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, PMV Pharmaceuticals, Inc. reported net sales of 0.00 million and a net profit of -60.88 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 176.08 million and total assets of 191.29 million.

Read More

What does PMV Pharmaceuticals, Inc. do?

22-Jun-2025

PMV Pharmaceuticals, Inc. is a precision oncology company developing small molecule therapies targeting p53 mutations. It has a market cap of $56.63 million and reported a net profit loss of $17 million as of March 2025.

Overview: <BR>PMV Pharmaceuticals, Inc. is a precision oncology company focused on discovering and developing small molecule, tumor-agnostic therapies targeting p53 mutations, operating within the Miscellaneous industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 56.63 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.00 <BR>Return on Equity: -38.02% <BR>Price to Book: 0.35<BR><BR>Contact Details: <BR>Address: 8 Clarke Drive, CRANBURY NJ: 08512 <BR>Tel: 1 609 6426664 <BR>Fax: 1 302 6365454 <BR>Website: http://pmvpharma.com/

Read More

Who are in the management team of PMV Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of PMV Pharmaceuticals, Inc. is led by Dr. David Mack, who is the President, Chief Executive Officer, Co-Founder, and Director.

As of March 2022, the management team of PMV Pharmaceuticals, Inc. includes Dr. David Mack, who serves as the President, Chief Executive Officer, Co-Founder, and Director.

Read More

Is PMV Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, PMV Pharmaceuticals, Inc. shows a mildly bullish trend overall, with mixed signals from various indicators, but has significantly underperformed the S&P 500 with a year-to-date return of -18.54%.

As of 10 September 2025, the technical trend for PMV Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. The daily moving averages are also mildly bullish. However, the weekly Dow Theory shows a mildly bearish stance, which contrasts with the monthly view that is mildly bullish. The Bollinger Bands present a mixed signal, being mildly bullish on the weekly and bearish on the monthly. <BR><BR>Overall, the indicators suggest a mildly bullish stance, but the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -18.54% versus the S&P's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 74 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.01

stock-summary
Return on Equity

-57.52%

stock-summary
Price to Book

0.53

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-21 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-17.42%
0%
-17.42%
6 Months
39.24%
0%
39.24%
1 Year
-20.5%
0%
-20.5%
2 Years
-46.67%
0%
-46.67%
3 Years
-87.24%
0%
-87.24%
4 Years
-94.28%
0%
-94.28%
5 Years
-96.89%
0%
-96.89%

PMV Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is PMV Pharmaceuticals, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for PMV Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. The daily moving averages are also mildly bullish. However, the weekly Dow Theory shows a mildly bearish stance, which contrasts with the monthly view that is mildly bullish. The Bollinger Bands present a mixed signal, being mildly bullish on the weekly and bearish on the monthly. Overall, the indicators suggest a mildly bullish stance, but the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -18.54% versus the S&P's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-201.90%
EBIT to Interest (avg)
-69.74
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0
Tax Ratio
23.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.31
EV to EBIT
1.23
EV to EBITDA
1.25
EV to Capital Employed
-109.63
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-38.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 32 Schemes (23.21%)

Foreign Institutions

Held by 50 Foreign Institutions (15.46%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -1,666.67% vs 93.10% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.80",
          "val2": "-19.80",
          "chgp": "-15.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.20",
          "val2": "-1.20",
          "chgp": "-1,666.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 14.93% vs 5.87% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-84.30",
          "val2": "-78.90",
          "chgp": "-6.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-58.70",
          "val2": "-69.00",
          "chgp": "14.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-22.80
-19.80
-15.15%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-21.20
-1.20
-1,666.67%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -1,666.67% vs 93.10% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-84.30
-78.90
-6.84%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-58.70
-69.00
14.93%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 14.93% vs 5.87% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About PMV Pharmaceuticals, Inc. stock-summary
stock-summary
PMV Pharmaceuticals, Inc.
Miscellaneous
PMV Pharmaceuticals, Inc. is a precision oncology company. The Company is focused on discovering and developing small molecule, tumor-agnostic therapies targeting p53 mutations. It’s lead product candidate, PC14586, is designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild-type p53. It is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates that structurally correct other p53 hotspot mutations to restore their wild-type function. Its second program, R273H, targets the p53 R273H hotspot mutation.
Company Coordinates stock-summary
Company Details
8 Clarke Drive , CRANBURY NJ : 08512
stock-summary
Tel: 1 609 6426664
stock-summary
http://pmvpharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."